^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up

Published date:
07/28/2019
Excerpt:
For three ALK-rearranged patients, ipilimumab PFS was 24.1 months.
Trial ID: